CRYSVITA Specific Use Results Survey Long Term Surveillance with FGF23 Related Hypophosphatemia Rickets and Osteomalacia

CRYSVITA Specific Use Results Survey Long Term Surveillance with FGF23 Related Hypophosphatemia Rickets and Osteomalacia - CRYSVITA Specific Use Results Survey Long Term Surveillance with FGF23 Related Hypophosphatemia Rickets and Osteomalacia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050528

Enrollment

250

Registered

2023-03-07

Start date

2019-12-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

FGF23-related hypophosphatemic rickets and osteomalacia patient

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients of "FGF23-associated hypophosphatemic rickets/osteomalacia" treated with this drug.

Exclusion criteria

Exclusion criteria: Duplicate cases Cases at facilities not under contract Cases exceeding the number of contracted cases Registered cases from non-contracted physicians Cases whose registration reception date is outside the contract period

Design outcomes

Primary

Measure	Time frame
Safety Incidence of adverse reactions and infectious disease Incidence of serious adverse drug reactions Safety specifications Factors considered affecting the safety Effectiveness Serum P concentration reached the normal range during the observation period Change in height (measured only for children under 18 years of age) Efficacy by Patient Background Factors that may influence the assessment of effectiveness Changes in complications related to the primary disease (fractures, bone pain, joint pain, stiffness, etc.) during the observation period	—

Measure

Time frame

Safety Incidence of adverse reactions and infectious disease Incidence of serious adverse drug reactions Safety specifications Factors considered affecting the safety Effectiveness Serum P concentration reached the normal range during the observation period Change in height (measured only for children under 18 years of age) Efficacy by Patient Background Factors that may influence the assessment of effectiveness Changes in complications related to the primary disease (fractures, bone pain, joint pain, stiffness, etc.) during the observation period

—

Countries

Japan

Contacts

Public ContactHiroshi Kuwazawa

Kyowa Kirin Co., Ltd. Pharmacovigilance Division

hiroshi.kuwazawa.wd@kyowakirin.com+81-70-3143-9628

Outcome results